Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About David House

David House is recorded as CFO at Armata Pharmaceuticals, Inc. (ARMP). Armata Pharmaceuticals, Inc. reported in an 8-K filed July 20, 2026 that David House was appointed Chief Financial Officer, effective July 17, 2026. Armata Pharmaceuticals, Inc. reported in an 8-K filed August 15, 2024 that David House was appointed Senior Vice President, Finance, effective August 16, 2024. The proxy statement of Armata Pharmaceuticals, Inc. reports total compensation of $269,438 for David House in fiscal 2024, including a base salary of $131,250.

“On July 17, 2026, the Board of Directors (the “Board”) of Armata Pharmaceuticals, Inc. (the “Company”) promoted and appointed David House as the Company’s Chief Financial Officer, effective July 17, 2026.”
Armata Pharmaceuticals, Inc. Form 8-K, filed July 20, 2026 · Read the filing
“On July 31, 2024, Armata Pharmaceuticals, Inc. (the “Company”) entered into an employment letter agreement (the “Agreement”) with David House, pursuant to which he has agreed to serve as the Company’s Senior Vice President, Finance, effective August 16, 2024 (the “Effective Date”).”
Armata Pharmaceuticals, Inc. Form 8-K, filed August 15, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Armata Pharmaceuticals, Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Armata Pharmaceuticals, Inc. (ARMP) $131,250 $269,438

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.